BioJiva Reports Results of Pilot Phase II Clinical Trial of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)

BioJiva reported data from its completed multicenter, randomized, double-blind, placebo-controlled pilot Phase II clinical trial evaluating RT001, the company’s lead development candidate, in patients with ALS.